The need for aminoglycosides in combination with β-lactams for high-risk, febrile neutropaenic patients with leukaemia

European Journal of Cancer, Supplement

Volumn 5, Issue 2, 2007, Pages 13-22

  Drgona, Lubos ^a   Paul, Mical ^b   Bucaneve, Giampaolo ^c   Calandra, Thierry ^d   Menichetti, Francesco ^e  

^a CANCER RESEARCH INSTITUTE   (Slovakia)

^b RABIN MEDICAL CENTER   (Israel)

^c Ospedale Silvestrini   (Italy)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e CISANELLO HOSPITAL   (Italy)

Author keywords

Acute leukaemia; Aminoglycoside; Combination therapy; Febrile neutropaenia; Monotherapy

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; BETA LACTAM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; GENTAMICIN; IMIPENEM; MEROPENEM; NETILMICIN; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TIMENTIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; EUROPE; FEBRILE NEUTROPENIA; GRAM NEGATIVE INFECTION; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; LYMPHOMA; MEDICAL PRACTICE; META ANALYSIS; MONOTHERAPY; NEPHROTOXICITY; PRIORITY JOURNAL; PSEUDOMONAS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEPTIC SHOCK; SUPERINFECTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 34547602924     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2007.06.003     Document Type: Article

References (66)

1. Schimpff S., Satterlee W., Young V.M., et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 284 (1971) 1061-1065
2. Schimpff S.C. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 80 (1986) 13-20
3. Hughes W.T., Armstrong D., Bodey G.P., et al. From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropaenic patients with unexplained fever. J Infect Dis 161 (1990) 381-396
4. Hughes W.T., Armstrong D., Bodey G.P., et al. guidelines for the use of antimicrobial agents in neutropaenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 25 (1997) 551-573
5. Klastersky J., Paesmans M., Rubenstein E.B., et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropaenic cancer patients. J Clin Oncol 18 (2000) 3038-3051
6. Talcott J.A., Siegel R.D., Finberg R., et al. Risk assessment in cancer patients with fever and neutropaenia: a prospective, two-centre validation of a prediction rule. J Clin Oncol 10 (1992) 316-322
7. Vidal L., Paul M., Ben dor I., et al. Oral versus intravenous antibiotic treatment for febrile neutropaenia in cancer patients: a systematic review and meta-analysis of randomized trials. J Antimicrob Chemother 54 (2004) 29-37
8. Ramphal R. Changes in the etiology of bacteraemia in febrile neutropaenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 9 Suppl. 1 (2004) S25-S31
9. Hughes W.T., Armstrong D., Bodey G.P., et al. guidelines for the use of antimicrobial agents in neutropaenic patients with cancer. Clin Infect Dis 34 (2002) 730-751
10. Paul M., Soares-Weiser K., Grozinsky S., et al. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev 2 (2003) CD003038
11. Furno P., Bucaneve G., and Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropaenic patients: a meta-analysis. Lancet Infect Dis 2 (2002) 231-242
12. Wrzesien-Kus A.J., Wierzbowska K., and Robak A.T. Cefepine in monotherapy or in combination with amikacine as the empirical treatment of febrile neutropaenic patients. Acta Haematol Pol 32 (2001) 165-172
13. Kliasova G, Savchenko VLL, Mendeleeva L, et al. (Moscow, RUS). Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for febrile neutropaenic bone marrow transplant patients. In: 11th European Congress of clinical microbiology and infectious diseases; 2001.
14. Kiehl M.G., Bischoff M., Basara N., et al. A prospective randomized trial comparing the efficacy and safety of piperacillin/tazobactam versus piperacillin/tazobactam plus netilmicin in the treatment of febrile neutropenia in allogeneic stem cell recipients. 41st interscience conference on antimicrobial agents and chemotherapy. Chicago (2001), Americal Society for Microbiology p. 267
15. Bru J.P., Michallet M., Legrand C., et al. A prospective randomized study comparing the efficacy of Timentin alone or in combination with amikacin in the treatment of febrile neutropaenic patients. J Antimicrob Chemother 17 Suppl. C (1986) 203-209
16. Bilgir O, Kadikoylu V, Bilgir F. The comparison of imipenem with piperacillin/tazobactam and amikacin combination in patients with haematological malignancies in the treatment of febrile neutropaenia. In: 10th Congress of the European haematology association, Stockholm, Sweden; 2005 [abstract no. 1021].
17. Gaytan-Martinez JE, Mateos-Garcia E, Casanova LJ, et al. Efficacy of empirical therapy with cefepime compared with ceftazidime plus amikacin in febrile neutropaenic patients. In: Annual meeting of the American society of haematology; 2002 [abstract no. 3655].
18. Gorschluter M., Hahn C., Fixson A., et al. Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropaenic patients with haematological malignancies: a randomized comparison. Support Care Cancer 11 (2003) 362-370
19. Miller J.A., Butler T., Beveridge R.A., et al. Efficacy and tolerability of imipenem-cilastatin versus ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropaenic cancer patients. Clin Ther 15 (1993) 486-499
20. Tamura K., Imajo K., Akiyama N., et al. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropaenia. Clin Infect Dis 39 Suppl. 1 (2004) S15-S24
21. Antmen B, Sasmaz I, Tanyeli A et al. Initial empiric antibiotic treatments in childhood febrile neutropaenia: meropenem versus ceftazidime plus amikacin combination. In: 11th European congress of clinical microbiology and infectious diseases; 2001.
22. Corapcioglu F., and Sarper N. Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropaenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost. Pediatr Haematol Oncol 22 (2005) 59-70
23. El Haddad A. Comparison of cefoperazone-sulbactam versus piperacillin plus amikacin as empiric therapy in pediatric febrile neutropaenic cancer patients. Curr Therapeut Res Clin Exp 56 (1995) 1094-1099
24. Hung K.C., Chiu H.H., Tseng Y.C., et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropaenic fever in children with malignancy. J Microbiol Immunol Infect 36 (2003) 254-259
25. Koehler M., Bubala H., Sonta-Jakimczyk D., et al. Assessment of the efficacy of treating infections in haematopoietic proliferative diseases: Monotherapy with ceftazidime and tobramycin combined with amoxycillin/ampicillin [in Polish]. Pol Tyg Lek 45 (1990) 417-420
26. Petrilli A.S., Cypriano M., Dantas L.S., et al. Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropaenia in pediatric patients with leukaemia and lymphoma. Braz J Infect Dis 7 (2003) 111-120
27. Ahmed-El Borollosy N, El Beshlawy A, El Mahallawy H, et al. Outpatient single dose ceftriaxone and amikacin versus imipenem/cilastatin monotherapy in the empiric treatment of pediatric patients with high risk fever and neutropenia. A randomized, prospective clinical trial. In: American society of haematology annual meeting abstracts; 2003.
28. Ahmed-El Borollosy N, El Beshlawy A, El Mahallawy H, et al. Outpatient single dose ceftriaxone and amikacin versus imipenem/cilastatin monotherapy in the empiric treatment of pediatric patients with high risk fever aneutropaenia. A randomized, prospective clinical trial. In: American society of clinical oncology conference; 2004.
29. Jimeno A, Arcediano A, Gomez C et al. Randomized study of cefepime versus ceftazidime plus amikacin in febrile neutropaenic patients with solid tumors treated with high dose chemotherapy and peripheral blood stem cell support. In: Proceedings of the American society of clinical oncology; 2003 [abstract no. 3387].
30. Rodriguez W., Gomez H., Silva M.E., et al. Cefotaxima versus cefalotina-gentamicina en el primer episodio febril de pacientes con tumores solidos y neutropaenia de corta duracion / Cefotaxime vs Cephalotin-Gentamicin in the first febrile episode of patients having solid tumors and short-term neutropaenia. Acta Cancerol 25 (1995) 61-68
31. Berezin EN, Almeida FJ, Santos AG et al. Asessment of Cefepime monotherapy versus combined therapy with ceftriaxone and aminoglicosyde in oncologic children and adolescents with febrile neutropaenia. In: 13th European congress of clinical microbiology and infectious diseases; 2003.
32. Sanz M.A., Bermudez A., Rovira M., et al. Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropaenic patients: results of the COSTINE study. Curr Med Res Opin 21 (2005) 645-655
33. Caldas J, Fernandes T, Monteiro A et al. Management of febrile neutropaenia: single agent or combination therapy. In: American society of haematology annual meeting abstracts; 2004 [abstract no. 5063].
34. Badea M, Badea D. Ceftriaxone in febrile granulocytopenic patients with haematological malignancies. In: European haematology association conference; 2002 [abstract no. 707].
35. Akin H, Korten V, Akan H et al. Cefepime combined with a short (four days) or long course of isepamicin for empirical therapy of high-risk febrile neutropaenic haematological cancer patients: a prospective, randomised, multicentre study. In: European congress of clinical microbiology and infectious diseases; 2005 [abstract no. R2061].
36. Fainstein V., Bodey G.P., Elting L., et al. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients. J Antimicrob Chemother 12 Suppl. A (1983) 101-110
37. Sung L., Dupuis L.L., Bliss B., et al. Randomized controlled trial of once- versus thrice-daily tobramycin in febrile neutropaenic children undergoing stem cell transplantation. J Natl Cancer Inst 95 (2003) 1869-1877
38. Ariffin H., Arasu A., Mahfuzah M., et al. Single-daily ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropaenia in children with cancer. J Paediatr Child Health 37 (2001) 38-43
39. Charnas R., Luthi A.R., and Ruch W. Once daily ceftriaxone plus amikacin versus three times daily ceftazidime plus amikacin for treatment of febrile neutropaenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children. Pediatr Infect Dis J 16 (1997) 346-353
40. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 119 (1993) 584-593
41. Rozdzinski E., Kern W.V., Reichle A., et al. Once-daily versus thrice-daily dosing of netilmicin in combination with beta-lactam antibiotics as empirical therapy for febrile neutropaenic patients. J Antimicrob Chemother 31 (1993) 585-598
42. Gibson J., Johnson L., Snowdon L., et al. Single daily ceftriaxone and tobramycin in the empirical management of febrile neutropaenic patients: a randomised trial. Int J Haematol 58 (1993) 63-72
43. Torfoss D., and Hoiby E.A. Tobramycin once versus three times a day given with penicillin G to cancer patients with febrile neutropaenia: a prospective randomised multicentre trial. 16th European congress of clinical microbiology and infectious diseases. Nice, France (2006), European Society of Clinical Microbiology and Infectious Diseases 698
44. Hansen M.A., Carstensen F., Coolidge C., Dahlager J., and Frimodt-Moller J. Once versus thrice-daily dosing of netilmicin in febrile immunocompromised patients: a randomized, controlled study of efficacy and safety. Journal of Drug Development 1 Suppl. 3 (1988) 119-124
45. Hatala R., Dinh T.T., and Cook D.J. Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. Clin Infect Dis 24 (1997) 810-815
46. Ali M.Z., and Goetz M.B. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 24 (1997) 796-809
47. Bailey T.C., Little J.R., Littenberg B., et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 24 (1997) 786-795
48. Barza M., Ioannidis J.P., Cappelleri J.C., et al. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 312 (1996) 338-345
49. Hatala R., Dinh T., and Cook D.J. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 124 (1996) 717-725
50. Ferriols-Lisart R., and Alos-Alminana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health Syst Pharm 53 (1996) 1141-1150
51. Galloe A.M., Graudal N., Christensen H.R., et al. Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol 48 (1995) 39-43
52. Munckhof W.J., Grayson M.L., and Turnidge J.D. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 37 (1996) 645-663
53. Link H., Bohme A., Cornely O.A., et al. Antimicrobial therapy of unexplained fever in neutropaenic patients-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Haematol 82 Suppl. 2 (2003) S105-S117
54. NCCN. National Comprehensive Cancer Network. Clinical practice guidelines in oncology - fever and neutropenia. Available from: http://www.nccn.org/.
55. Rolston K.V., and Bodey G.P. Comment on: Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 58 (2006) 478
56. Paul M., Yahav D., Fraser A., et al. Empirical antibiotic monotherapy for febrile neutropaenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 57 (2006) 176-189
57. Edwards S.J., Emmas C.E., and Campbell H.E. Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections. Curr Med Res Opin 21 (2005) 785-794
58. Viscoli C., Machetti M., Cappellano P., et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 38 (2004) 913-916
59. Safdar N., Handelsman J., and Maki D.G. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 4 (2004) 519-527
60. Klastersky J., Zinner S.H., Calandra T., et al. Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. Eur J Cancer Clin Oncol 24 Suppl. 1 (1988) S35-S45
61. Cometta A., Zinner S., de Bock R., et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 39 (1995) 445-452
62. Del Favero A., Menichetti F., Martino P., et al. A multicentre, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropaenia. Clin Infect Dis 33 (2001) 1295-1301
63. Elting L.S., Rubenstein E.B., Rolston K.V., et al. Outcomes of bacteraemia in patients with cancer and neutropaenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25 (1997) 247-259
64. Cornelissen J.J., de Graeff A., Verdonck L.F., et al. Imipenem versus gentamicin combined with either cefuroxime or cephalothin as initial therapy for febrile neutropaenic patients. Antimicrob Agents Chemother 36 (1992) 801-807
65. Norrby S.R., Vandercam B., Louie T., et al. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropaenic patients: a prospective, randomized multi-clinic study. Scand J Infect Dis 52 Suppl. (1987) 65-78
66. Bliziotis I.A., Samonis G., Vardakas K.Z., et al. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 41 (2005) 149-158